Mylan just took a blow to its 2017 hopes, and GSK got a boost: The FDA turned away Mylan's copycat version of the megablockbuster Advair.

A top Senate Democrat is throwing the weight of her office behind efforts to dig into opioid marketing practices.

The #FierceMadness DTC ad tournament is down to the final four with ads from BI, Allergan, Takeda and J&J still in the hunt.

Last October, Depomed switched up its board to appease activist Starboard Value. But Starboard didn’t stop there, and now Depmed has a new CEO.

The new multiple sclerosis med Roche has been anticipating—and the market shake-up other drugmakers have been dreading—is here.

Vertex is consolidating its R&D operations to three sites and shuttering one facility in Canada in a move that will claim 70 jobs there.

Set to launch at a price of $37,000, the atopic dermatitis therapy Dupixent (dupilumab) can now embark on its path to expected sales of $3 billion-plus.

Pfizer is looking to reclassify Viagra (sildenafil) as a pharmacy medicine in the U.K., almost a decade after its first OTC request.